Dr. Giraldi shares why there are better drugs to treat female sexual desire problems available in Europe.
I think you have to ask the authorities in the States because they did not approve the testosterone patch but also to justify when it was, when it was applied in Europe there were more safety data on the patch. So regulatory authorities in the States, in Europe thought that they had enough evidence to approve this. So I don’t know why it’s different in Europe.
I think one of the reasons is that when it was presented in Europe there were more data on it and because it was not approved the first time in the States the company might be a little scared to go and have, try to get it approved again, I don’t know whether that’s the question but that’s one of the reasons I could think of.
About Dr. Giraldi, M.D., Ph.D.:
Dr. Annamaria Giraldi, M.D., Ph.D., specializes in female sexual dysfunction. Her research interests include the connection between diseases and female sexual function, and the treatment of sexual desire problems in women.
Dr. Giraldi is associate editor for The Journal of Sexual Medicine. She is a member of the European Society for Sexual Medicine and the International Society for the Study of Women’s Sexual Health.